US0197701065 - Common Stock
3.41 +0.02 (+0.59%)
After market: 3.43 +0.02 (+0.59%)
ALLOGENE THERAPEUTICS INC
NASDAQ:ALLO (9/28/2023, 5:32:13 PM)After market: 3.43 +0.02 (+0.59%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 359 full-time employees. The company went IPO on 2018-10-11. The firm is focused on the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. The company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell-driven hematological malignancies. The company is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.
ALLOGENE THERAPEUTICS INC
210 East Grand Avenue
South San Francisco CALIFORNIA 94080
CEO: David Chang
Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to...
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
/PRNewswire/ -- Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric...
Here you can normally see the latest stock twits on ALLO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.